| Spencer Audiology Clinic, Ps | |
|
2114 James St, Bellingham, WA 98225-4140 | |
| (360) 527-8525 | |
| (360) 527-8526 |
| Full Name | Spencer Audiology Clinic, Ps |
|---|---|
| Type | Facility |
| Speciality | Clinic/center - Hearing And Speech |
| Location | 2114 James St, Bellingham, Washington |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649460114 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Secondary |
| 261QH0700X | Clinic/center - Hearing And Speech | LD00003945 (Washington) | Primary |
| Provider Name | Pamela H Spencer |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1427170877 PECOS PAC ID: 1951336064 Enrollment ID: I20050928000171 |
News Archive
Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
Many pediatricians know their patients use complementary and alternative therapies (CAM) to improve their health, yet most do not feel comfortable discussing or recommending these therapies, according to a study published in the November issue of Ambulatory Pediatrics.
Bristol-Myers Squibb Company announced today the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc. at a purchase price of $26.00 per share.
Martin Jarry was a police officer in Quebec. He coached a youth hockey team. He was used to being active, used to working out, used to being strong. But when Jarry was diagnosed with inclusion body myositis (IBM), he had to do some serious re-evaluating of his activities.
› Verified 1 days ago
| Provider Name | Suzanne E Jennings |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1740304336 PECOS PAC ID: 4284709767 Enrollment ID: I20080818000661 |
News Archive
Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
Many pediatricians know their patients use complementary and alternative therapies (CAM) to improve their health, yet most do not feel comfortable discussing or recommending these therapies, according to a study published in the November issue of Ambulatory Pediatrics.
Bristol-Myers Squibb Company announced today the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc. at a purchase price of $26.00 per share.
Martin Jarry was a police officer in Quebec. He coached a youth hockey team. He was used to being active, used to working out, used to being strong. But when Jarry was diagnosed with inclusion body myositis (IBM), he had to do some serious re-evaluating of his activities.
› Verified 1 days ago
| Provider Name | Shonie E Hannah |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1477677052 PECOS PAC ID: 1658446141 Enrollment ID: I20080818000741 |
News Archive
Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
Many pediatricians know their patients use complementary and alternative therapies (CAM) to improve their health, yet most do not feel comfortable discussing or recommending these therapies, according to a study published in the November issue of Ambulatory Pediatrics.
Bristol-Myers Squibb Company announced today the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc. at a purchase price of $26.00 per share.
Martin Jarry was a police officer in Quebec. He coached a youth hockey team. He was used to being active, used to working out, used to being strong. But when Jarry was diagnosed with inclusion body myositis (IBM), he had to do some serious re-evaluating of his activities.
› Verified 1 days ago
| Provider Name | Ian S Cox |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1326766932 PECOS PAC ID: 5294101986 Enrollment ID: I20221020002748 |
News Archive
Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
Many pediatricians know their patients use complementary and alternative therapies (CAM) to improve their health, yet most do not feel comfortable discussing or recommending these therapies, according to a study published in the November issue of Ambulatory Pediatrics.
Bristol-Myers Squibb Company announced today the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc. at a purchase price of $26.00 per share.
Martin Jarry was a police officer in Quebec. He coached a youth hockey team. He was used to being active, used to working out, used to being strong. But when Jarry was diagnosed with inclusion body myositis (IBM), he had to do some serious re-evaluating of his activities.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Spencer Audiology Clinic, Ps 2114 James St, Bellingham, WA 98225-4140 Ph: (360) 527-8525 | Spencer Audiology Clinic, Ps 2114 James St, Bellingham, WA 98225-4140 Ph: (360) 527-8525 |
News Archive
Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
Many pediatricians know their patients use complementary and alternative therapies (CAM) to improve their health, yet most do not feel comfortable discussing or recommending these therapies, according to a study published in the November issue of Ambulatory Pediatrics.
Bristol-Myers Squibb Company announced today the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc. at a purchase price of $26.00 per share.
Martin Jarry was a police officer in Quebec. He coached a youth hockey team. He was used to being active, used to working out, used to being strong. But when Jarry was diagnosed with inclusion body myositis (IBM), he had to do some serious re-evaluating of his activities.
› Verified 1 days ago